Floatz logo

TRASTUZUMAB

Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Carboplatin
Rapa Therapeutics LLC
Phase 1/2B
Abiraterone Acetate
MacroGenics
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 22 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →